2023 annual financial data
Lyell Immunopharma 2023 Net margin
Direct answer
Net margin was -180,486.15%.
Operating income was -247.01M USD and net income was -234.63M USD.
Operating cash flow was -163.69M USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 130,000 USD
- Operating income
- -247.01M USD
- Net income
- -234.63M USD
- Operating cash flow
- -163.69M USD